Jabbour on Tailoring Treatment With TKIs in CML and Ph+ ALL

Jul 19, 08:24 PM

Dr. Jabbour discusses the optimal use of ponatinib in chronic myeloid leukemia and data from the 2021 ASCO Annual Meeting with the combination of blinatumomab and ponatinib in Ph-positive acute lymphoblastic leukemia.